HSG Research

Huntington Study Group Data & Findings

Site Survey: Patients Supported by HD Centers (2019)

During March 2019, the HSG surveyed their 86 United States based sites (HD Centers), with 63 responding to reveal an average of 135 HD patients per center. Thus:

  • A total of 11,633 HD patients are estimated to be served by the HSG’s 86 US locations.
  • If the numerator is the number of patients seeking care (11,633 in the United States) and the denominator is the approximately 30,000 patients in the US with symptomatic HD (based on the literature), then it appears that there are 70% of people with HD who evade care.

Huntington Study Group Research

Below is an interactive list of publications from PubMed.gov in which the Huntington Study Group is cited. Click on the hyperlink to access abstracts and papers.

Note: Some papers require a paid subscription to view.

  1. Stimming, EF, Claassen, DO, Kayson, E, Goldstein, J, Mehanna, R, Zhang, H et al.. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023;22 (6):494-504. doi: 10.1016/S1474-4422(23)00127-8. PubMed PMID:37210099 .
  2. Adams, JL, Kangarloo, T, Tracey, B, O'Donnell, P, Volfson, D, Latzman, RD et al.. Using a smartwatch and smartphone to assess early Parkinson's disease in the WATCH-PD study. NPJ Parkinsons Dis. 2023;9 (1):64. doi: 10.1038/s41531-023-00497-x. PubMed PMID:37069193 PubMed Central PMC10108794.
  3. Hauser, RA, Ondo, WG, Zhang, Y, Bowling, A, Navia, B, Pappert, E et al.. Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson's Disease: Is the Prophylactic Use of an Antiemetic Necessary?. J Parkinsons Dis. 2023;13 (3):403-414. doi: 10.3233/JPD-223537. PubMed PMID:36970914 PubMed Central PMC10200146.
  4. Sokol, LL, Troost, JP, Bega, D, Kluger, BM, Prigerson, HG, Nance, M et al.. Advance Care Planning and Health-Related Quality of Life in Huntington Disease: Results from a Multicenter National Study. Palliat Med Rep. 2023;4 (1):79-88. doi: 10.1089/pmr.2022.0034. PubMed PMID:36969738 PubMed Central PMC10036076.
  5. Dorsey, ER, Zafar, M, Lettenberger, SE, Pawlik, ME, Kinel, D, Frissen, M et al.. Trichloroethylene: An Invisible Cause of Parkinson's Disease?. J Parkinsons Dis. 2023;13 (2):203-218. doi: 10.3233/JPD-225047. PubMed PMID:36938742 PubMed Central PMC10041423.
  6. Estevez-Fraga, C, Elmalem, MS, Papoutsi, M, Durr, A, Rees, EM, Hobbs, NZ et al.. Progressive alterations in white matter microstructure across the timecourse of Huntington's disease. Brain Behav. 2023;13 (4):e2940. doi: 10.1002/brb3.2940. PubMed PMID:36917716 PubMed Central PMC10097137.
  7. Anderson, KE, Stevenson, M, Varghese, R, Hebron, ML, Koppel, E, McCartin, M et al.. Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington's Disease Patients. Metabolites. 2022;12 (12):. doi: 10.3390/metabo12121225. PubMed PMID:36557263 PubMed Central PMC9781133.
  8. Frey, J, Black, KJ, Malaty, IA. TikTok Tourette's: Are We Witnessing a Rise in Functional Tic-Like Behavior Driven by Adolescent Social Media Use?. Psychol Res Behav Manag. 2022;15 :3575-3585. doi: 10.2147/PRBM.S359977. PubMed PMID:36505669 PubMed Central PMC9733629.
  9. Malaty, IA, Anderson, S, Bennett, SM, Budman, CL, Coffey, BJ, Coffman, KA et al.. Diagnosis and Management of Functional Tic-Like Phenomena. J Clin Med. 2022;11 (21):. doi: 10.3390/jcm11216470. PubMed PMID:36362696 PubMed Central PMC9656241.
  10. Seeberger, L, Corey-Bloom, J, O'Brien, M, Slowiejko, D, Schlang, D, Booth, MS et al.. Assessing the state of care for Huntington disease in the United States: Results from a survey of practices treating Huntington disease patients. Clin Park Relat Disord. 2022;7 :100165. doi: 10.1016/j.prdoa.2022.100165. PubMed PMID:36262527 PubMed Central PMC9574766.
  11. Frank, S, Testa, C, Edmondson, MC, Goldstein, J, Kayson, E, Leavitt, BR et al.. The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study. CNS Drugs. 2022;36 (11):1207-1216. doi: 10.1007/s40263-022-00956-8. PubMed PMID:36242718 PubMed Central PMC9653309.
  12. Gibson, JS, Flanigan, JL, Patrie, JT, Dalrymple, WA, Harrison, MB. Predictors of anxiety in Parkinson's disease: results from a 3-year longitudinal cohort study. Neurol Sci. 2023;44 (2):547-556. doi: 10.1007/s10072-022-06427-8. PubMed PMID:36216970 PubMed Central PMC9842547.
  13. Feigin, A, Evans, EE, Fisher, TL, Leonard, JE, Smith, ES, Reader, A et al.. Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial. Nat Med. 2022; :. doi: 10.1038/s41591-022-02070-0. PubMed PMID:36195687 .
  14. Lobanov, SV, McAllister, B, McDade-Kumar, M, Landwehrmeyer, GB, Orth, M, Rosser, AE et al.. Huntington's disease age at motor onset is modified by the tandem hexamer repeat in TCERG1. NPJ Genom Med. 2022;7 (1):53. doi: 10.1038/s41525-022-00317-w. PubMed PMID:36064847 PubMed Central PMC9445028.
  15. Yang, Y, Yuan, Y, Zhang, G, Wang, H, Chen, YC, Liu, Y et al.. Artificial intelligence-enabled detection and assessment of Parkinson's disease using nocturnal breathing signals. Nat Med. 2022;28 (10):2207-2215. doi: 10.1038/s41591-022-01932-x. PubMed PMID:35995955 PubMed Central PMC9556299.
  16. Feigin, A, Evans, EE, Fisher, TL, Leonard, JE, Smith, ES, Reader, A et al.. Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial. Nat Med. 2022;28 (10):2183-2193. doi: 10.1038/s41591-022-01919-8. PubMed PMID:35941373 PubMed Central PMC9361919.
  17. Roussos, G, Herrero, TR, Hill, DL, Dowling, AV, L T M Müller, M, Evers, LJW et al.. Identifying and characterising sources of variability in digital outcome measures in Parkinson's disease. NPJ Digit Med. 2022;5 (1):93. doi: 10.1038/s41746-022-00643-4. PubMed PMID:35840653 PubMed Central PMC9284971.
  18. Tabrizi, SJ, Estevez-Fraga, C, van Roon-Mom, WMC, Flower, MD, Scahill, RI, Wild, EJ et al.. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities. Lancet Neurol. 2022;21 (7):645-658. doi: 10.1016/S1474-4422(22)00121-1. PubMed PMID:35716694 PubMed Central PMC7613206.
  19. Krafft, GA, Jerecic, J, Siemers, E, Cline, EN. ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer's Disease. Front Neurosci. 2022;16 :848215. doi: 10.3389/fnins.2022.848215. PubMed PMID:35557606 PubMed Central PMC9088393.
  20. Furby, H, Siadimas, A, Rutten-Jacobs, L, Rodrigues, FB, Wild, EJ. Natural history and burden of Huntington's disease in the UK: A population-based cohort study. Eur J Neurol. 2022;29 (8):2249-2257. doi: 10.1111/ene.15385. PubMed PMID:35514071 PubMed Central PMC9542098.
  21. McAllister, B, Donaldson, J, Binda, CS, Powell, S, Chughtai, U, Edwards, G et al.. Exome sequencing of individuals with Huntington's disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset. Nat Neurosci. 2022;25 (4):446-457. doi: 10.1038/s41593-022-01033-5. PubMed PMID:35379994 PubMed Central PMC8986535.
  22. Hill, DL, Stephenson, D, Brayanov, J, Claes, K, Badawy, R, Sardar, S et al.. Metadata Framework to Support Deployment of Digital Health Technologies in Clinical Trials in Parkinson's Disease. Sensors (Basel). 2022;22 (6):. doi: 10.3390/s22062136. PubMed PMID:35336307 PubMed Central PMC8954603.
  23. Page, A, Yung, N, Auinger, P, Venuto, C, Glidden, A, Macklin, E et al.. A Smartphone Application as an Exploratory Endpoint in a Phase 3 Parkinson's Disease Clinical Trial: A Pilot Study. Digit Biomark. 2022;6 (1):1-8. doi: 10.1159/000521232. PubMed PMID:35224425 PubMed Central PMC8832247.
  24. Langbehn, DR, Registry Investigators of the European Huntington Disease Network. Longer CAG repeat length is associated with shorter survival after disease onset in Huntington disease. Am J Hum Genet. 2022;109 (1):172-179. doi: 10.1016/j.ajhg.2021.12.002. PubMed PMID:34942093 PubMed Central PMC8764269.
  25. Adams, JL, Dinesh, K, Snyder, CW, Xiong, M, Tarolli, CG, Sharma, S et al.. A real-world study of wearable sensors in Parkinson's disease. NPJ Parkinsons Dis. 2021;7 (1):106. doi: 10.1038/s41531-021-00248-w. PubMed PMID:34845224 PubMed Central PMC8629990.
  26. Anon. Abstracts of the 28th Annual Meeting of the Huntington Study Group, November 4-6, 2021. J Huntingtons Dis. 2021;10 (s1):S1-S41. doi: 10.3233/JHD219003. PubMed PMID:34719506 .
  27. De Miranda, BR, Goldman, SM, Miller, GW, Greenamyre, JT, Dorsey, ER. Preventing Parkinson's Disease: An Environmental Agenda. J Parkinsons Dis. 2022;12 (1):45-68. doi: 10.3233/JPD-212922. PubMed PMID:34719434 PubMed Central PMC8842749.
  28. Coffey, B, Jankovic, J, Claassen, DO, Jimenez-Shahed, J, Gertz, BJ, Garofalo, EA et al.. Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open. 2021;4 (10):e2129397. doi: 10.1001/jamanetworkopen.2021.29397. PubMed PMID:34661664 PubMed Central PMC8524312.
  29. Jankovic, J, Coffey, B, Claassen, DO, Jimenez-Shahed, J, Gertz, BJ, Garofalo, EA et al.. Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open. 2021;4 (10):e2128204. doi: 10.1001/jamanetworkopen.2021.28204. PubMed PMID:34609495 PubMed Central PMC8493441.
  30. Scorr, LM, Factor, SA, Parra, SP, Kaye, R, Paniello, RC, Norris, SA et al.. Oromandibular Dystonia: A Clinical Examination of 2,020 Cases. Front Neurol. 2021;12 :700714. doi: 10.3389/fneur.2021.700714. PubMed PMID:34603182 PubMed Central PMC8481678.
  31. Commiskey, P, Armstrong, AW, Coker, TR, Dorsey, ER, Fortney, JC, Gaines, KJ et al.. A Blueprint for the Conduct of Large, Multisite Trials in Telemedicine. J Med Internet Res. 2021;23 (9):e29511. doi: 10.2196/29511. PubMed PMID:34542417 PubMed Central PMC8491114.
  32. Myers, PS, Jackson, JJ, Clover, AK, Lessov-Schlaggar, CN, Foster, ER, Maiti, B et al.. Distinct progression patterns across Parkinson disease clinical subtypes. Ann Clin Transl Neurol. 2021;8 (8):1695-1708. doi: 10.1002/acn3.51436. PubMed PMID:34310084 PubMed Central PMC8351397.
  33. Sokol, LL, Troost, JP, Kluger, BM, Applebaum, AJ, Paulsen, JS, Bega, D et al.. Meaning and purpose in Huntington's disease: a longitudinal study of its impact on quality of life. Ann Clin Transl Neurol. 2021;8 (8):1668-1679. doi: 10.1002/acn3.51424. PubMed PMID:34288600 PubMed Central PMC8351386.
  34. Dorsey, ER. The new platforms of health care. NPJ Digit Med. 2021;4 (1):112. doi: 10.1038/s41746-021-00478-5. PubMed PMID:34267312 PubMed Central PMC8282598.
  35. Buchanan, DA, Goldstein, J, Pfalzer, AC, Lin, YC, Kang, H, Claassen, DO et al.. Empowering the Clinical Research Coordinator in Academic Medical Centers. Mayo Clin Proc Innov Qual Outcomes. 2021;5 (2):265-273. doi: 10.1016/j.mayocpiqo.2020.09.014. PubMed PMID:33997626 PubMed Central PMC8105545.
  36. Guttman, M, Pedrazzoli, M, Ponomareva, M, Pelletier, M, Townson, L, Mukelabai, K et al.. The Impact of Upcoming Treatments in Huntington's Disease: Resource Capacity Limitations and Access to Care Implications. J Huntingtons Dis. 2021;10 (2):303-311. doi: 10.3233/JHD-200462. PubMed PMID:33843690 PubMed Central PMC8293639.
  37. Sieberts, SK, Schaff, J, Duda, M, Pataki, BÁ, Sun, M, Snyder, P et al.. Crowdsourcing digital health measures to predict Parkinson's disease severity: the Parkinson's Disease Digital Biomarker DREAM Challenge. NPJ Digit Med. 2021;4 (1):53. doi: 10.1038/s41746-021-00414-7. PubMed PMID:33742069 PubMed Central PMC7979931.
  38. Tarakad, A, Jankovic, J. Recent advances in understanding and treatment of Parkinson's disease. Fac Rev. 2020;9 :6. doi: 10.12703/b/9-6. PubMed PMID:33659938 PubMed Central PMC7886054.
  39. Tanner, CM, Cummings, SR, Schwarzschild, MA, Brown, EG, Dorsey, ER, Espay, AJ et al.. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. NPJ Parkinsons Dis. 2021;7 (1):16. doi: 10.1038/s41531-021-00162-1. PubMed PMID:33649343 PubMed Central PMC7921548.
  40. Junker, J, Berman, BD, Hall, J, Wahba, DW, Brandt, V, Perlmutter, JS et al.. Quality of life in isolated dystonia: non-motor manifestations matter. J Neurol Neurosurg Psychiatry. 2021; :. doi: 10.1136/jnnp-2020-325193. PubMed PMID:33563813 PubMed Central PMC8356023.
  41. Stephenson, D, Alexander, R, Aggarwal, V, Badawy, R, Bain, L, Bhatnagar, R et al.. Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science. Digit Biomark. 2020;4 (Suppl 1):28-49. doi: 10.1159/000512500. PubMed PMID:33442579 PubMed Central PMC7768153.
  42. Wang, A, Molho, E, Yang, Y, Pilitsis, J, Ramirez-Zamora, A. Dissociative Tremor Response with Pallidal Deep Brain Stimulation in Parkinson's Disease. Tremor Other Hyperkinet Mov (N Y). 2020;10 :53. doi: 10.5334/tohm.568. PubMed PMID:33362947 PubMed Central PMC7747761.
  43. Schneider, RB, Omberg, L, Macklin, EA, Daeschler, M, Bataille, L, Anthwal, S et al.. Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD). Ann Clin Transl Neurol. 2021;8 (2):308-320. doi: 10.1002/acn3.51236. PubMed PMID:33350601 PubMed Central PMC7886038.
  44. Anon. Correction to: Huntington Study Group Abstracts 2020. Neurotherapeutics. 2020;17 (Suppl 1):42. doi: 10.1007/s13311-020-00970-y. PubMed PMID:33200289 PubMed Central PMC7851221.
  45. GBD 2017 US Neurological Disorders Collaborators, Feigin, VL, Vos, T, Alahdab, F, Amit, AML, Bärnighausen, TW et al.. Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study. JAMA Neurol. 2021;78 (2):165-176. doi: 10.1001/jamaneurol.2020.4152. PubMed PMID:33136137 PubMed Central PMC7607495.
  46. Anon. Huntington Study Group Abstracts 2020. Neurotherapeutics. 2020;17 (Suppl 1):1-41. doi: 10.1007/s13311-020-00945-z. PubMed PMID:33083994 PubMed Central PMC7574988.
  47. Campbell, MC, Myers, PS, Weigand, AJ, Foster, ER, Cairns, NJ, Jackson, JJ et al.. Parkinson disease clinical subtypes: key features & clinical milestones. Ann Clin Transl Neurol. 2020;7 (8):1272-1283. doi: 10.1002/acn3.51102. PubMed PMID:32602253 PubMed Central PMC7448190.
  48. Dorsey, ER, Omberg, L, Waddell, E, Adams, JL, Adams, R, Ali, MR et al.. Deep Phenotyping of Parkinson's Disease. J Parkinsons Dis. 2020;10 (3):855-873. doi: 10.3233/JPD-202006. PubMed PMID:32444562 PubMed Central PMC7458535.
  49. Bashir, HH, Jankovic, J. Treatment of Tardive Dyskinesia. Neurol Clin. 2020;38 (2):379-396. doi: 10.1016/j.ncl.2020.01.004. PubMed PMID:32279716 .
  50. Coran, P, Goldsack, JC, Grandinetti, CA, Bakker, JP, Bolognese, M, Dorsey, ER et al.. Advancing the Use of Mobile Technologies in Clinical Trials: Recommendations from the Clinical Trials Transformation Initiative. Digit Biomark. 2019;3 (3):145-154. doi: 10.1159/000503957. PubMed PMID:32095773 PubMed Central PMC7011727.
  51. Gordon, MF, Grachev, ID, Mazeh, I, Dolan, Y, Reilmann, R, Loupe, PS et al.. Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor Devices. Digit Biomark. 2019;3 (3):103-115. doi: 10.1159/000502136. PubMed PMID:32095771 PubMed Central PMC7011722.
  52. Kabelac, Z, Tarolli, CG, Snyder, C, Feldman, B, Glidden, A, Hsu, CY et al.. Passive Monitoring at Home: A Pilot Study in Parkinson Disease. Digit Biomark. 2019;3 (1):22-30. doi: 10.1159/000498922. PubMed PMID:32095766 PubMed Central PMC7015389.
  53. McGarry, A, McDermott, MP, Kieburtz, K, Peng, J, Cudkowicz, M, Huntington Study Group 2CARE Investigators and Coordinators et al.. Baseline Variables Associated with Functional Decline in 2CARE, A Randomized Clinical Trial in Huntington's Disease. J Huntingtons Dis. 2020;9 (1):47-58. doi: 10.3233/JHD-190391. PubMed PMID:31985471 PubMed Central PMC8216232.
  54. Tanner, CM, Pahwa, R, Hauser, RA, Oertel, WH, Isaacson, SH, Jankovic, J et al.. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. J Parkinsons Dis. 2020;10 (2):543-558. doi: 10.3233/JPD-191841. PubMed PMID:31929122 PubMed Central PMC7242830.
  55. Anderson, KE, Griffin, J, Kinel, A, Shaikh, AR, Olofintuyi, T, Ramirez, S et al.. Quality of Care for Huntington's Disease in the United States: Findings from a National Survey of Patients and Caregivers. J Huntingtons Dis. 2019;8 (4):509-519. doi: 10.3233/JHD-190380. PubMed PMID:31594241 .
  56. Langbehn, DR, Stout, JC, Gregory, S, Mills, JA, Durr, A, Leavitt, BR et al.. Association of CAG Repeats With Long-term Progression in Huntington Disease. JAMA Neurol. 2019;76 (11):1375-1385. doi: 10.1001/jamaneurol.2019.2368. PubMed PMID:31403680 PubMed Central PMC6692683.
  57. Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Electronic address: gusella@helix.mgh.harvard.edu, Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset. Cell. 2019;178 (4):887-900.e14. doi: 10.1016/j.cell.2019.06.036. PubMed PMID:31398342 PubMed Central PMC6700281.
  58. Kayson, E, Eberly, S, Anderson, KE, Marder, K, Shoulson, I, Oakes, D et al.. The Prospective Huntington At-Risk Observational Study (PHAROS): The Emotional Well-Being, Safety and Feasibility of Long-Term Research Participation. J Huntingtons Dis. 2019;8 (4):435-441. doi: 10.3233/JHD-190365. PubMed PMID:31381523 .
  59. van der Plas, E, Hamilton, MJ, Miller, JN, Koscik, TR, Long, JD, Cumming, S et al.. Brain Structural Features of Myotonic Dystrophy Type 1 and their Relationship with CTG Repeats. J Neuromuscul Dis. 2019;6 (3):321-332. doi: 10.3233/JND-190397. PubMed PMID:31306140 PubMed Central PMC7480174.
  60. Li, F, Li, K, Li, C, Luo, S, PREDICT-HD and ENROLL-HD Investigators of the Huntington Study Group. Predicting the Risk of Huntington's Disease with Multiple Longitudinal Biomarkers. J Huntingtons Dis. 2019;8 (3):323-332. doi: 10.3233/JHD-190345. PubMed PMID:31256145 PubMed Central PMC6718328.
  61. Shoulson, I, Eberly, S, Oakes, D, Kayson, E, Young, AB, PHAROS Investigators et al.. Phenotype-genotype discrepancies in the prospective Huntington at-risk observational study. Ann Clin Transl Neurol. 2019;6 (6):1046-1052. doi: 10.1002/acn3.781. PubMed PMID:31211168 PubMed Central PMC6562068.
  62. Klehmet, J, Beutner, S, Hoffmann, S, Dornauer, M, Paul, F, Reilmann, R et al.. Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy. BMC Neurol. 2019;19 (1):118. doi: 10.1186/s12883-019-1339-x. PubMed PMID:31176377 PubMed Central PMC6556046.
  63. Armstrong, MJ, Rastgardani, T, Gagliardi, AR, Marras, C. Barriers and facilitators of communication about off periods in Parkinson's disease: Qualitative analysis of patient, carepartner, and physician Interviews. PLoS One. 2019;14 (4):e0215384. doi: 10.1371/journal.pone.0215384. PubMed PMID:30998707 PubMed Central PMC6472878.
  64. Ciarochi, JA, Johnson, HJ, Calhoun, VD, Liu, J, Espinoza, FA, Bockholt, HJ et al.. Concurrent Cross-Sectional and Longitudinal Analyses of Multivariate White Matter Profiles and Clinical Functioning in Pre-Diagnosis Huntington Disease. J Huntingtons Dis. 2019;8 (2):199-219. doi: 10.3233/JHD-180332. PubMed PMID:30932891 .
  65. McGarry, A, McDermott, MP, Kieburtz, K, Fung, WLA, McCusker, E, Peng, J et al.. Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial. Neurology. 2019;92 (14):e1643-e1651. doi: 10.1212/WNL.0000000000007244. PubMed PMID:30850442 PubMed Central PMC6448454.
  66. Braisch, U, Muche, R, Rothenbacher, D, Landwehrmeyer, GB, Long, JD, Orth, M et al.. Identification of symbol digit modality test score extremes in Huntington's disease. Am J Med Genet B Neuropsychiatr Genet. 2019;180 (3):232-245. doi: 10.1002/ajmg.b.32719. PubMed PMID:30788902 .
  67. Reilmann, R, McGarry, A, Grachev, ID, Savola, JM, Borowsky, B, Eyal, E et al.. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019;18 (2):165-176. doi: 10.1016/S1474-4422(18)30391-0. PubMed PMID:30563778 .
  68. Long, JD, Mills, JA. Joint modeling of multivariate longitudinal data and survival data in several observational studies of Huntington's disease. BMC Med Res Methodol. 2018;18 (1):138. doi: 10.1186/s12874-018-0592-9. PubMed PMID:30445915 PubMed Central PMC6240282.
  69. Niemann, N, Jankovic, J. Botulinum Toxin for the Treatment of Hand Tremor. Toxins (Basel). 2018;10 (7):. doi: 10.3390/toxins10070299. PubMed PMID:30029483 PubMed Central PMC6070882.
  70. Ciarochi, JA, Liu, J, Calhoun, V, Johnson, H, Misiura, M, Bockholt, HJ et al.. High and Low Levels of an NTRK2-Driven Genetic Profile Affect Motor- and Cognition-Associated Frontal Gray Matter in Prodromal Huntington's Disease. Brain Sci. 2018;8 (7):. doi: 10.3390/brainsci8070116. PubMed PMID:29932126 PubMed Central PMC6071032.
  71. Snyder, CW, Dorsey, ER, Atreja, A. The Best Digital Biomarkers Papers of 2017. Digit Biomark. 2018;2 (2):64-73. doi: 10.1159/000489224. PubMed PMID:32095757 PubMed Central PMC7015358.
  72. Carlozzi, NE, Boileau, NR, Perlmutter, JS, Chou, KL, Stout, JC, Paulsen, JS et al.. Agreement between clinician-rated versus patient-reported outcomes in Huntington disease. J Neurol. 2018;265 (6):1443-1453. doi: 10.1007/s00415-018-8852-5. PubMed PMID:29687215 PubMed Central PMC5992091.
  73. Liu, J, Ciarochi, J, Calhoun, VD, Paulsen, JS, Bockholt, HJ, Johnson, HJ et al.. Genetics Modulate Gray Matter Variation Beyond Disease Burden in Prodromal Huntington's Disease. Front Neurol. 2018;9 :190. doi: 10.3389/fneur.2018.00190. PubMed PMID:29651271 PubMed Central PMC5884935.
  74. Tanner, C, Marder, K, Eberly, S, Biglan, K, Oakes, D, Shoulson, I et al.. Selected health and lifestyle factors, cytosine-adenine-guanine status, and phenoconversion in Huntington's disease. Mov Disord. 2018;33 (3):472-478. doi: 10.1002/mds.27239. PubMed PMID:29297592 PubMed Central PMC5986294.
  75. Stark, AJ, Claassen, DO. Positron emission tomography in Parkinson's disease: insights into impulsivity. Int Rev Psychiatry. 2017;29 (6):618-627. doi: 10.1080/09540261.2017.1398139. PubMed PMID:29206483 PubMed Central PMC6410706.
  76. Carlozzi, NE, Hahn, EA, Frank, SA, Perlmutter, JS, Downing, ND, McCormack, MK et al.. A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning. J Neurol. 2018;265 (1):98-107. doi: 10.1007/s00415-017-8677-7. PubMed PMID:29143208 PubMed Central PMC5762414.
  77. Schobel, SA, Palermo, G, Auinger, P, Long, JD, Ma, S, Khwaja, OS et al.. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology. 2017;89 (24):2495-2502. doi: 10.1212/WNL.0000000000004743. PubMed PMID:29142089 PubMed Central PMC5729794.
  78. Boileau, NR, Stout, JC, Paulsen, JS, Cella, D, McCormack, MK, Nance, MA et al.. Reliability and Validity of the HD-PRO-TriadTM, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntington's Disease. J Huntingtons Dis. 2017;6 (3):201-215. doi: 10.3233/JHD-170238. PubMed PMID:28968239 PubMed Central PMC6089522.
  79. Anon. Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative ataxia group, and tremor research group. Mov Disord. 2017;32 (9):e1-e19. doi: 10.1002/mds.27134. PubMed PMID:28887904 .
  80. Hersch, SM, Schifitto, G, Oakes, D, Bredlau, AL, Meyers, CM, Nahin, R et al.. The CREST-E study of creatine for Huntington disease: A randomized controlled trial. Neurology. 2017;89 (6):594-601. doi: 10.1212/WNL.0000000000004209. PubMed PMID:28701493 PubMed Central PMC5562960.
  81. Frank, S, Stamler, D, Kayson, E, Claassen, DO, Colcher, A, Davis, C et al.. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. JAMA Neurol. 2017;74 (8):977-982. doi: 10.1001/jamaneurol.2017.1352. PubMed PMID:28692723 PubMed Central PMC5710322.
  82. Wu, D, Faria, AV, Younes, L, Mori, S, Brown, T, Johnson, H et al.. Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease. Hum Brain Mapp. 2017;38 (10):5035-5050. doi: 10.1002/hbm.23713. PubMed PMID:28657159 PubMed Central PMC5766002.
  83. Jennings, D, Siderowf, A, Stern, M, Seibyl, J, Eberly, S, Oakes, D et al.. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort. JAMA Neurol. 2017;74 (8):933-940. doi: 10.1001/jamaneurol.2017.0985. PubMed PMID:28595287 PubMed Central PMC5710321.
  84. Li, K, Furr-Stimming, E, Paulsen, JS, Luo, S, PREDICT-HD Investigators of the Huntington Study Group. Dynamic Prediction of Motor Diagnosis in Huntington's Disease Using a Joint Modeling Approach. J Huntingtons Dis. 2017;6 (2):127-137. doi: 10.3233/JHD-170236. PubMed PMID:28582868 PubMed Central PMC5505650.
  85. Carlozzi, NE, Hahn, EA, Goodnight, SM, Kratz, AL, Paulsen, JS, Stout, JC et al.. Patient-reported outcome measures in Huntington disease: Quality of life in neurological disorders (Neuro-QoL) social functioning measures. Psychol Assess. 2018;30 (4):450-458. doi: 10.1037/pas0000479. PubMed PMID:28557480 PubMed Central PMC5708162.
  86. Carlozzi, NE, Ready, RE, Frank, S, Cella, D, Hahn, EA, Goodnight, SM et al.. Patient-reported outcomes in Huntington's disease: Quality of life in neurological disorders (Neuro-QoL) and Huntington's disease health-related quality of life (HDQLIFE) physical function measures. Mov Disord. 2017;32 (7):1096-1102. doi: 10.1002/mds.27046. PubMed PMID:28556412 PubMed Central PMC5605785.
  87. Westervelt, HJ, Bernier, RA, Faust, M, Gover, M, Bockholt, HJ, Zschiegner, R et al.. Data quality assurance and control in cognitive research: Lessons learned from the PREDICT-HD study. Int J Methods Psychiatr Res. 2017;26 (3):. doi: 10.1002/mpr.1534. PubMed PMID:28211597 PubMed Central PMC6258197.
  88. Anon. Abstracts from HSG 2016: Discovering Our Future, the 23rd Annual Meeting of the Huntington Study Group (HSG). Neurotherapeutics. 2017;14 (1):227-251. doi: 10.1007/s13311-016-0482-y. PubMed PMID:28083811 PubMed Central PMC5233626.
  89. Downing, NR, Lourens, S, De Soriano, I, Long, JD, Paulsen, JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group et al.. Phenotype Characterization of HD Intermediate Alleles in PREDICT-HD. J Huntingtons Dis. 2016;5 (4):357-368. doi: 10.3233/JHD-160185. PubMed PMID:27983559 PubMed Central PMC6258187.
  90. McGarry, A, McDermott, M, Kieburtz, K, de Blieck, EA, Beal, F, Marder, K et al.. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017;88 (2):152-159. doi: 10.1212/WNL.0000000000003478. PubMed PMID:27913695 PubMed Central PMC5224719.
  91. Braisch, U, Hay, B, Muche, R, Rothenbacher, D, Landwehrmeyer, GB, Long, JD et al.. Identification of extreme motor phenotypes in Huntington's disease. Am J Med Genet B Neuropsychiatr Genet. 2017;174 (3):283-294. doi: 10.1002/ajmg.b.32514. PubMed PMID:27868347 .
  92. Quaid, KA, Eberly, SW, Kayson-Rubin, E, Oakes, D, Shoulson, I, Huntington Study Group PHAROS Investigators and Coordinators et al.. Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS). Clin Genet. 2017;91 (6):824-831. doi: 10.1111/cge.12893. PubMed PMID:27740685 PubMed Central PMC5392180.
  93. Ciarochi, JA, Calhoun, VD, Lourens, S, Long, JD, Johnson, HJ, Bockholt, HJ et al.. Patterns of Co-Occurring Gray Matter Concentration Loss across the Huntington Disease Prodrome. Front Neurol. 2016;7 :147. doi: 10.3389/fneur.2016.00147. PubMed PMID:27708610 PubMed Central PMC5030293.
  94. Salem, L, Saleh, N, Désaméricq, G, Youssov, K, Dolbeau, G, Cleret, L et al.. Insulin-Like Growth Factor-1 but Not Insulin Predicts Cognitive Decline in Huntington's Disease. PLoS One. 2016;11 (9):e0162890. doi: 10.1371/journal.pone.0162890. PubMed PMID:27627435 PubMed Central PMC5023180.
  95. Harrington, DL, Long, JD, Durgerian, S, Mourany, L, Koenig, K, Bonner-Jackson, A et al.. Cross-sectional and longitudinal multimodal structural imaging in prodromal Huntington's disease. Mov Disord. 2016;31 (11):1664-1675. doi: 10.1002/mds.26803. PubMed PMID:27620011 PubMed Central PMC5115975.
  96. Carlozzi, NE, Schilling, SG, Lai, JS, Paulsen, JS, Hahn, EA, Perlmutter, JS et al.. HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Qual Life Res. 2016;25 (10):2441-2455. doi: 10.1007/s11136-016-1386-3. PubMed PMID:27522213 PubMed Central PMC6108175.
  97. Huntington Study Group, Frank, S, Testa, CM, Stamler, D, Kayson, E, Davis, C et al.. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016;316 (1):40-50. doi: 10.1001/jama.2016.8655. PubMed PMID:27380342 .
  98. Friedman, JH, Beck, JC, Chou, KL, Clark, G, Fagundes, CP, Goetz, CG et al.. Fatigue in Parkinson's disease: report from a mutidisciplinary symposium. NPJ Parkinsons Dis. 2016;2 :15025-. doi: 10.1038/npjparkd.2015.25. PubMed PMID:27239558 PubMed Central PMC4883681.
  99. Faria, AV, Ratnanather, JT, Tward, DJ, Lee, DS, van den Noort, F, Wu, D et al.. Linking white matter and deep gray matter alterations in premanifest Huntington disease. Neuroimage Clin. 2016;11 :450-460. doi: 10.1016/j.nicl.2016.02.014. PubMed PMID:27104139 PubMed Central PMC4827723.
  100. Carvalho, JO, Long, JD, Westervelt, HJ, Smith, MM, Bruce, JM, Kim, JI et al.. The impact of oculomotor functioning on neuropsychological performance in Huntington disease. J Clin Exp Neuropsychol. 2016;38 (2):217-26. doi: 10.1080/13803395.2015.1101054. PubMed PMID:26745770 PubMed Central PMC8091165.
  101. Huntington Study Group PHAROS Investigators, Biglan, KM, Shoulson, I, Kieburtz, K, Oakes, D, Kayson, E et al.. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016;73 (1):102-10. doi: 10.1001/jamaneurol.2015.2736. PubMed PMID:26569098 .
  102. Epping, EA, Kim, JI, Craufurd, D, Brashers-Krug, TM, Anderson, KE, McCusker, E et al.. Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data. Am J Psychiatry. 2016;173 (2):184-92. doi: 10.1176/appi.ajp.2015.14121551. PubMed PMID:26472629 PubMed Central PMC5465431.
  103. Liu, D, Long, JD, Zhang, Y, Raymond, LA, Marder, K, Rosser, A et al.. Motor onset and diagnosis in Huntington disease using the diagnostic confidence level. J Neurol. 2015;262 (12):2691-8. doi: 10.1007/s00415-015-7900-7. PubMed PMID:26410751 PubMed Central PMC4666501.
  104. Long, JD, Paulsen, JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Multivariate prediction of motor diagnosis in Huntington's disease: 12 years of PREDICT-HD. Mov Disord. 2015;30 (12):1664-72. doi: 10.1002/mds.26364. PubMed PMID:26340420 PubMed Central PMC4795466.
  105. Musso, M, Westervelt, HJ, Long, JD, Morgan, E, Woods, SP, Smith, MM et al.. Intra-individual Variability in Prodromal Huntington Disease and Its Relationship to Genetic Burden. J Int Neuropsychol Soc. 2015;21 (1):8-21. doi: 10.1017/S1355617714001076. PubMed PMID:26304055 PubMed Central PMC4549971.
  106. Matsui, JT, Vaidya, JG, Wassermann, D, Kim, RE, Magnotta, VA, Johnson, HJ et al.. Prefrontal cortex white matter tracts in prodromal Huntington disease. Hum Brain Mapp. 2015;36 (10):3717-32. doi: 10.1002/hbm.22835. PubMed PMID:26179962 PubMed Central PMC4583330.
  107. Dorsey, ER, Darwin, KC, Mohammed, S, Donohue, S, Tethal, A, Achey, MA et al.. Virtual research visits and direct-to-consumer genetic testing in Parkinson's disease. Digit Health. 2015;1 :2055207615592998. doi: 10.1177/2055207615592998. PubMed PMID:29942542 PubMed Central PMC5999055.
  108. Harrington, DL, Rubinov, M, Durgerian, S, Mourany, L, Reece, C, Koenig, K et al.. Network topology and functional connectivity disturbances precede the onset of Huntington's disease. Brain. 2015;138 (Pt 8):2332-46. doi: 10.1093/brain/awv145. PubMed PMID:26059655 PubMed Central PMC5022662.
  109. Low, PA, Reich, SG, Jankovic, J, Shults, CW, Stern, MB, Novak, P et al.. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015;14 (7):710-9. doi: 10.1016/S1474-4422(15)00058-7. PubMed PMID:26025783 PubMed Central PMC4472464.
  110. Kim, JI, Long, JD, Mills, JA, McCusker, E, Paulsen, JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group et al.. Multivariate clustering of progression profiles reveals different depression patterns in prodromal Huntington disease. Neuropsychology. 2015;29 (6):949-60. doi: 10.1037/neu0000199. PubMed PMID:26011117 PubMed Central PMC4640959.
  111. Kim, JI, Long, JD, Mills, JA, Downing, N, Williams, JK, Paulsen, JS et al.. Performance of the 12-item WHODAS 2.0 in prodromal Huntington disease. Eur J Hum Genet. 2015;23 (11):1584-7. doi: 10.1038/ejhg.2015.11. PubMed PMID:25735480 PubMed Central PMC4613468.
  112. Martinez-Ramirez, D, Giugni, JC, Hastings, E, Wagle Shukla, A, Malaty, IA, Okun, MS et al.. Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis. Tremor Other Hyperkinet Mov (N Y). 2014;4 :286. doi: 10.7916/D8H41Q4X. PubMed PMID:25562037 PubMed Central PMC4266684.
  113. Huntington Study Group Reach2HD Investigators. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14 (1):39-47. doi: 10.1016/S1474-4422(14)70262-5. PubMed PMID:25467848 .
  114. Paulsen, JS, Long, JD, Ross, CA, Harrington, DL, Erwin, CJ, Williams, JK et al.. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. Lancet Neurol. 2014;13 (12):1193-201. doi: 10.1016/S1474-4422(14)70238-8. PubMed PMID:25453459 PubMed Central PMC4373455.
  115. Koenig, KA, Lowe, MJ, Harrington, DL, Lin, J, Durgerian, S, Mourany, L et al.. Functional connectivity of primary motor cortex is dependent on genetic burden in prodromal Huntington disease. Brain Connect. 2014;4 (7):535-46. doi: 10.1089/brain.2014.0271. PubMed PMID:25072408 PubMed Central PMC4146393.
  116. Williams, JK, Kim, JI, Downing, N, Farias, S, Harrington, DL, Long, JD et al.. Everyday cognition in prodromal Huntington disease. Neuropsychology. 2015;29 (2):255-67. doi: 10.1037/neu0000102. PubMed PMID:25000321 PubMed Central PMC4286521.
  117. Paulsen, JS, Long, JD, Johnson, HJ, Aylward, EH, Ross, CA, Williams, JK et al.. Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study. Front Aging Neurosci. 2014;6 :78. doi: 10.3389/fnagi.2014.00078. PubMed PMID:24795630 PubMed Central PMC4000999.
  118. Martinez-Ramirez, D, Giugni, J, Vedam-Mai, V, Wagle Shukla, A, Malaty, IA, McFarland, NR et al.. The "brittle response" to Parkinson's disease medications: characterization and response to deep brain stimulation. PLoS One. 2014;9 (4):e94856. doi: 10.1371/journal.pone.0094856. PubMed PMID:24733172 PubMed Central PMC3986256.
  119. Georgiou-Karistianis, N, Long, JD, Lourens, SG, Stout, JC, Mills, JA, Paulsen, JS et al.. Movement sequencing in Huntington disease. World J Biol Psychiatry. 2014;15 (6):459-71. doi: 10.3109/15622975.2014.895042. PubMed PMID:24678867 PubMed Central PMC4389285.
  120. Nagel, M, Rumpf, HJ, Kasten, M. Acute psychosis in a verified Huntington disease gene carrier with subtle motor signs: psychiatric criteria should be considered for the diagnosis. Gen Hosp Psychiatry. 2014;36 (3):361.e3-4. doi: 10.1016/j.genhosppsych.2014.01.008. PubMed PMID:24576988 .
  121. Downing, NR, Kim, JI, Williams, JK, Long, JD, Mills, JA, Paulsen, JS et al.. WHODAS 2.0 in prodromal Huntington disease: measures of functioning in neuropsychiatric disease. Eur J Hum Genet. 2014;22 (8):958-63. doi: 10.1038/ejhg.2013.275. PubMed PMID:24327189 PubMed Central PMC4350592.
  122. Defazio, G, Jankovic, J, Giel, JL, Papapetropoulos, S. Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkinet Mov (N Y). 2013;3 :. doi: 10.7916/D80C4TGJ. PubMed PMID:24255801 PubMed Central PMC3822401.
  123. Dorsey, ER, Beck, CA, Darwin, K, Nichols, P, Brocht, AF, Biglan, KM et al.. Natural history of Huntington disease. JAMA Neurol. 2013;70 (12):1520-30. doi: 10.1001/jamaneurol.2013.4408. PubMed PMID:24126537 .
  124. Marder, K, Gu, Y, Eberly, S, Tanner, CM, Scarmeas, N, Oakes, D et al.. Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol. 2013;70 (11):1382-8. doi: 10.1001/jamaneurol.2013.3487. PubMed PMID:24000094 PubMed Central PMC4040231.
  125. McCusker, EA, Gunn, DG, Epping, EA, Loy, CT, Radford, K, Griffith, J et al.. Unawareness of motor phenoconversion in Huntington disease. Neurology. 2013;81 (13):1141-7. doi: 10.1212/WNL.0b013e3182a55f05. PubMed PMID:23966256 PubMed Central PMC3795599.
  126. Moscovitch-Lopatin, M, Goodman, RE, Eberly, S, Ritch, JJ, Rosas, HD, Matson, S et al.. HTRF analysis of soluble huntingtin in PHAROS PBMCs. Neurology. 2013;81 (13):1134-40. doi: 10.1212/WNL.0b013e3182a55ede. PubMed PMID:23966247 PubMed Central PMC3795598.
  127. Paulsen, JS, Smith, MM, Long, JD, PREDICT HD investigators and Coordinators of the Huntington Study Group. Cognitive decline in prodromal Huntington Disease: implications for clinical trials. J Neurol Neurosurg Psychiatry. 2013;84 (11):1233-9. doi: 10.1136/jnnp-2013-305114. PubMed PMID:23911948 PubMed Central PMC3795884.
  128. Waln, O, Jankovic, J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3 :. doi: 10.7916/D88P5Z71. PubMed PMID:23858394 PubMed Central PMC3709416.
  129. Epping, EA, Mills, JA, Beglinger, LJ, Fiedorowicz, JG, Craufurd, D, Smith, MM et al.. Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study. J Psychiatr Res. 2013;47 (10):1423-31. doi: 10.1016/j.jpsychires.2013.05.026. PubMed PMID:23790259 PubMed Central PMC3808084.
  130. Bonner-Jackson, A, Long, JD, Westervelt, H, Tremont, G, Aylward, E, Paulsen, JS et al.. Cognitive reserve and brain reserve in prodromal Huntington's disease. J Int Neuropsychol Soc. 2013;19 (7):739-50. doi: 10.1017/S1355617713000507. PubMed PMID:23702309 PubMed Central PMC3720793.
  131. Biglan, KM, Zhang, Y, Long, JD, Geschwind, M, Kang, GA, Killoran, A et al.. Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci. 2013;5 :12. doi: 10.3389/fnagi.2013.00012. PubMed PMID:23565093 PubMed Central PMC3613616.
  132. Gluhm, S, Goldstein, J, Loc, K, Colt, A, Liew, CV, Corey-Bloom, J et al.. Cognitive performance on the mini-mental state examination and the montreal cognitive assessment across the healthy adult lifespan. Cogn Behav Neurol. 2013;26 (1):1-5. doi: 10.1097/WNN.0b013e31828b7d26. PubMed PMID:23538566 PubMed Central PMC3638088.
  133. Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov Disord. 2013;28 (10):1407-15. doi: 10.1002/mds.25362. PubMed PMID:23450660 .
  134. Goh, AM, Chiu, E, Yastrubetskaya, O, Erwin, C, Williams, JK, Juhl, AR et al.. Perception, experience, and response to genetic discrimination in Huntington's disease: the Australian results of The International RESPOND-HD study. Genet Test Mol Biomarkers. 2013;17 (2):115-21. doi: 10.1089/gtmb.2012.0288. PubMed PMID:23289616 PubMed Central PMC3552166.
  135. Younes, L, Ratnanather, JT, Brown, T, Aylward, E, Nopoulos, P, Johnson, H et al.. Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis. Hum Brain Mapp. 2014;35 (3):792-809. doi: 10.1002/hbm.22214. PubMed PMID:23281100 PubMed Central PMC3715588.
  136. Aylward, EH, Harrington, DL, Mills, JA, Nopoulos, PC, Ross, CA, Long, JD et al.. Regional atrophy associated with cognitive and motor function in prodromal Huntington disease. J Huntingtons Dis. 2013;2 (4):477-89. doi: 10.3233/JHD-130076. PubMed PMID:25062732 PubMed Central PMC4412155.
  137. HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network. A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. JAMA Neurol. 2013;70 (1):25-33. doi: 10.1001/2013.jamaneurol.382. PubMed PMID:23108692 .
  138. Cooper, SE, McIntyre, CC, Fernandez, HH, Vitek, JL. Association of deep brain stimulation washout effects with Parkinson disease duration. JAMA Neurol. 2013;70 (1):95-9. doi: 10.1001/jamaneurol.2013.581. PubMed PMID:23070397 PubMed Central PMC5148628.
  139. Brossman, B, Williams, JK, Downing, N, Mills, JA, Paulsen, JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group et al.. Development of the Huntington disease work function scale. J Occup Environ Med. 2012;54 (10):1300-8. doi: 10.1097/JOM.0b013e31825f30ab. PubMed PMID:22995807 PubMed Central PMC3466392.
  140. Smith, MM, Mills, JA, Epping, EA, Westervelt, HJ, Paulsen, JS, PREDICT-HD Investigators of the Huntington Study Group et al.. Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease. Neuropsychology. 2012;26 (5):664-9. doi: 10.1037/a0029218. PubMed PMID:22846033 PubMed Central PMC3806339.
  141. Lee, JH, Lee, JM, Ramos, EM, Gillis, T, Mysore, JS, Kishikawa, S et al.. TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochem Biophys Res Commun. 2012;424 (3):404-8. doi: 10.1016/j.bbrc.2012.06.120. PubMed PMID:22771793 PubMed Central PMC3752397.
  142. Harrington, DL, Smith, MM, Zhang, Y, Carlozzi, NE, Paulsen, JS, PREDICT-HD Investigators of the Huntington Study Group et al.. Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry. 2012;83 (6):612-9. doi: 10.1136/jnnp-2011-301732. PubMed PMID:22451099 PubMed Central PMC3812822.
  143. Long, JD, Matson, WR, Juhl, AR, Leavitt, BR, Paulsen, JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group et al.. 8OHdG as a marker for Huntington disease progression. Neurobiol Dis. 2012;46 (3):625-34. doi: 10.1016/j.nbd.2012.02.012. PubMed PMID:22414782 PubMed Central PMC3784019.
  144. Rowe, KC, Paulsen, JS, Langbehn, DR, Wang, C, Mills, J, Beglinger, LJ et al.. Patterns of serotonergic antidepressant usage in prodromal Huntington disease. Psychiatry Res. 2012;196 (2-3):309-14. doi: 10.1016/j.psychres.2011.09.005. PubMed PMID:22397915 PubMed Central PMC3763706.
  145. Kloos, AD, Kegelmeyer, DA, White, SE, Kostyk, SK. The impact of different types of assistive devices on gait measures and safety in Huntington's disease. PLoS One. 2012;7 (2):e30903. doi: 10.1371/journal.pone.0030903. PubMed PMID:22363511 PubMed Central PMC3281896.
  146. Huntington Study Group COHORT Investigators, Dorsey, E. Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study. PLoS One. 2012;7 (2):e29522. doi: 10.1371/journal.pone.0029522. PubMed PMID:22359536 PubMed Central PMC3281013.
  147. Lee, JM, Ramos, EM, Lee, JH, Gillis, T, Mysore, JS, Hayden, MR et al.. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 2012;78 (10):690-5. doi: 10.1212/WNL.0b013e318249f683. PubMed PMID:22323755 PubMed Central PMC3306163.
  148. Anon. Fifth Annual Huntington Disease Clinical Research Symposium. Organized by the Huntington Study Group. Neurotherapeutics. 2012;9 (1):226-39. doi: 10.1007/s13311-011-0083-8. PubMed PMID:22302517 PubMed Central PMC4883046.
  149. Biglan, KM, Dorsey, ER, Evans, RV, Ross, CA, Hersch, S, Shoulson, I et al.. Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10. J Huntingtons Dis. 2012;1 (1):65-9. doi: 10.3233/JHD-2012-120007. PubMed PMID:25063191 PubMed Central PMC4115297.
  150. Aylward, EH, Liu, D, Nopoulos, PC, Ross, CA, Pierson, RK, Mills, JA et al.. Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol Psychiatry. 2012;71 (9):822-8. doi: 10.1016/j.biopsych.2011.07.030. PubMed PMID:21907324 PubMed Central PMC3237730.
  151. Zhang, Y, Long, JD, Mills, JA, Warner, JH, Lu, W, Paulsen, JS et al.. Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet. 2011;156B (7):751-63. doi: 10.1002/ajmg.b.31232. PubMed PMID:21858921 PubMed Central PMC3174494.
  152. Carlozzi, NE, Stout, JC, Mills, JA, Duff, K, Beglinger, LJ, Aylward, EH et al.. Estimating premorbid IQ in the prodromal phase of a neurodegenerative disease. Clin Neuropsychol. 2011;25 (5):757-77. doi: 10.1080/13854046.2011.577811. PubMed PMID:21660882 PubMed Central PMC3159182.
  153. Fiedorowicz, JG, Mills, JA, Ruggle, A, Langbehn, D, Paulsen, JS, PREDICT-HD Investigators of the Huntington Study Group et al.. Suicidal behavior in prodromal Huntington disease. Neurodegener Dis. 2011;8 (6):483-90. doi: 10.1159/000327754. PubMed PMID:21659725 PubMed Central PMC3186721.
  154. Downing, N, Smith, MM, Beglinger, LJ, Mills, J, Duff, K, Rowe, KC et al.. Perceived stress in prodromal Huntington disease. Psychol Health. 2012;27 (2):196-209. doi: 10.1080/08870446.2010.529141. PubMed PMID:21623544 PubMed Central PMC3165107.
  155. Wetzel, HH, Gehl, CR, Dellefave-Castillo, L, Schiffman, JF, Shannon, KM, Paulsen, JS et al.. Suicidal ideation in Huntington disease: the role of comorbidity. Psychiatry Res. 2011;188 (3):372-6. doi: 10.1016/j.psychres.2011.05.006. PubMed PMID:21605914 PubMed Central PMC3790459.
  156. Goodman, L, Sia, C, Carnes, R, Vetter, L, Taubman, F, Venuto, CS et al.. Advocacy Recruiting for Huntington's Disease Clinical Trials. PLoS Curr. 2011;3 :RRN1230. doi: 10.1371/currents.RRN1230. PubMed PMID:21532913 PubMed Central PMC3082401.
  157. Nopoulos, PC, Aylward, EH, Ross, CA, Mills, JA, Langbehn, DR, Johnson, HJ et al.. Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain. 2011;134 (Pt 1):137-42. doi: 10.1093/brain/awq280. PubMed PMID:20923788 PubMed Central PMC3025719.
  158. Aylward, EH, Nopoulos, PC, Ross, CA, Langbehn, DR, Pierson, RK, Mills, JA et al.. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry. 2011;82 (4):405-10. doi: 10.1136/jnnp.2010.208264. PubMed PMID:20884680 PubMed Central PMC3105627.
  159. Quaid, KA, Swenson, MM, Sims, SL, Harrison, JM, Moskowitz, C, Stepanov, N et al.. What were you thinking?: individuals at risk for Huntington Disease talk about having children. J Genet Couns. 2010;19 (6):606-17. doi: 10.1007/s10897-010-9312-2. PubMed PMID:20734119 PubMed Central PMC3686108.
  160. Williams, JK, Erwin, C, Juhl, A, Mills, J, Brossman, B, Paulsen, JS et al.. Personal factors associated with reported benefits of Huntington disease family history or genetic testing. Genet Test Mol Biomarkers. 2010;14 (5):629-36. doi: 10.1089/gtmb.2010.0065. PubMed PMID:20722493 PubMed Central PMC2957234.
  161. Huntington Study Group DOMINO Investigators. A futility study of minocycline in Huntington's disease. Mov Disord. 2010;25 (13):2219-24. doi: 10.1002/mds.23236. PubMed PMID:20721920 PubMed Central PMC8801051.
  162. Nopoulos, PC, Aylward, EH, Ross, CA, Johnson, HJ, Magnotta, VA, Juhl, AR et al.. Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis. 2010;40 (3):544-54. doi: 10.1016/j.nbd.2010.07.014. PubMed PMID:20688164 PubMed Central PMC2955824.
  163. Soneson, C, Fontes, M, Zhou, Y, Denisov, V, Paulsen, JS, Kirik, D et al.. Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiol Dis. 2010;40 (3):531-43. doi: 10.1016/j.nbd.2010.07.013. PubMed PMID:20682340 PubMed Central PMC2955781.
  164. Huntington Study Group Pre2CARE Investigators, Hyson, HC, Kieburtz, K, Shoulson, I, McDermott, M, Ravina, B et al.. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Mov Disord. 2010;25 (12):1924-8. doi: 10.1002/mds.22408. PubMed PMID:20669312 .
  165. Paulsen, JS, Wang, C, Duff, K, Barker, R, Nance, M, Beglinger, L et al.. Challenges assessing clinical endpoints in early Huntington disease. Mov Disord. 2010;25 (15):2595-603. doi: 10.1002/mds.23337. PubMed PMID:20623772 PubMed Central PMC2978744.
  166. Duff, K, Paulsen, J, Mills, J, Beglinger, LJ, Moser, DJ, Smith, MM et al.. Mild cognitive impairment in prediagnosed Huntington disease. Neurology. 2010;75 (6):500-7. doi: 10.1212/WNL.0b013e3181eccfa2. PubMed PMID:20610833 PubMed Central PMC2918475.
  167. Beglinger, LJ, O'Rourke, JJ, Wang, C, Langbehn, DR, Duff, K, Paulsen, JS et al.. Earliest functional declines in Huntington disease. Psychiatry Res. 2010;178 (2):414-8. doi: 10.1016/j.psychres.2010.04.030. PubMed PMID:20471695 PubMed Central PMC3629818.
  168. Williams, JK, Erwin, C, Juhl, AR, Mengeling, M, Bombard, Y, Hayden, MR et al.. In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet. 2010;153B (6):1150-9. doi: 10.1002/ajmg.b.31080. PubMed PMID:20468062 PubMed Central PMC3035936.
  169. Erwin, C, Williams, JK, Juhl, AR, Mengeling, M, Mills, JA, Bombard, Y et al.. Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet. 2010;153B (5):1081-93. doi: 10.1002/ajmg.b.31079. PubMed PMID:20468061 PubMed Central PMC3593716.
  170. Duff, K, Paulsen, JS, Beglinger, LJ, Langbehn, DR, Wang, C, Stout, JC et al.. "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci. 2010;22 (2):196-207. doi: 10.1176/jnp.2010.22.2.196. PubMed PMID:20463114 PubMed Central PMC2871328.
  171. Frank, S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol. 2009;9 :62. doi: 10.1186/1471-2377-9-62. PubMed PMID:20021666 PubMed Central PMC2804668.
  172. Marder, K, Zhao, H, Eberly, S, Tanner, CM, Oakes, D, Shoulson, I et al.. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology. 2009;73 (5):385-92. doi: 10.1212/WNL.0b013e3181b04aa2. PubMed PMID:19652143 PubMed Central PMC2725927.
  173. Biglan, KM, Ross, CA, Langbehn, DR, Aylward, EH, Stout, JC, Queller, S et al.. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord. 2009;24 (12):1763-72. doi: 10.1002/mds.22601. PubMed PMID:19562761 PubMed Central PMC3048804.
  174. Langbehn, DR, Hayden, MR, Paulsen, JS, and the PREDICT-HD Investigators of the Huntington Study Group. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2010;153B (2):397-408. doi: 10.1002/ajmg.b.30992. PubMed PMID:19548255 PubMed Central PMC3048807.
  175. Klöppel, S, Chu, C, Tan, GC, Draganski, B, Johnson, H, Paulsen, JS et al.. Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease. Neurology. 2009;72 (5):426-31. doi: 10.1212/01.wnl.0000341768.28646.b6. PubMed PMID:19188573 PubMed Central PMC2817939.
  176. Dorsey, ER, Beck, CA, Adams, M, Chadwick, G, de Blieck, EA, McCallum, C et al.. Communicating clinical trial results to research participants. Arch Neurol. 2008;65 (12):1590-5. doi: 10.1001/archneurol.2008.503. PubMed PMID:19064746 .
  177. Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol. 2008;65 (12):1582-9. doi: 10.1001/archneur.65.12.1582. PubMed PMID:19064745 .
  178. Oster, E, Dorsey, ER, Bausch, J, Shinaman, A, Kayson, E, Oakes, D et al.. Fear of health insurance loss among individuals at risk for Huntington disease. Am J Med Genet A. 2008;146A (16):2070-7. doi: 10.1002/ajmg.a.32422. PubMed PMID:18627059 PubMed Central PMC2574833.
  179. Paulsen, JS, Langbehn, DR, Stout, JC, Aylward, E, Ross, CA, Nance, M et al.. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79 (8):874-80. doi: 10.1136/jnnp.2007.128728. PubMed PMID:18096682 PubMed Central PMC2569211.
  180. Erwin, C, Hersch, S, Event Monitoring Committee of the Huntington Study Group. Monitoring reportable events and unanticipated problems: the PHAROS and PREDICT studies of Huntington disease. IRB. 2007;29 (3):11-6. . PubMed PMID:17847637 .
  181. Johnson, SA, Stout, JC, Solomon, AC, Langbehn, DR, Aylward, EH, Cruce, CB et al.. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain. 2007;130 (Pt 7):1732-44. doi: 10.1093/brain/awm107. PubMed PMID:17584778 .
  182. Langbehn, DR, Paulsen, JS, Huntington Study Group. Predictors of diagnosis in Huntington disease. Neurology. 2007;68 (20):1710-7. doi: 10.1212/01.wnl.0000261918.90053.96. PubMed PMID:17502553 .
  183. Duff, K, Paulsen, JS, Beglinger, LJ, Langbehn, DR, Stout, JC, Predict-HD Investigators of the Huntington Study Group et al.. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry. 2007;62 (12):1341-6. doi: 10.1016/j.biopsych.2006.11.034. PubMed PMID:17481592 .
  184. Solomon, AC, Stout, JC, Johnson, SA, Langbehn, DR, Aylward, EH, Brandt, J et al.. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia. 2007;45 (8):1767-76. doi: 10.1016/j.neuropsychologia.2006.12.015. PubMed PMID:17303196 PubMed Central PMC2570315.
  185. Beglinger, LJ, Langbehn, DR, Duff, K, Stierman, L, Black, DW, Nehl, C et al.. Probability of obsessive and compulsive symptoms in Huntington's disease. Biol Psychiatry. 2007;61 (3):415-8. doi: 10.1016/j.biopsych.2006.04.034. PubMed PMID:16839521 .
  186. Huntington Study Group PHAROS Investigators. At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. Arch Neurol. 2006;63 (7):991-6. doi: 10.1001/archneur.63.7.991. PubMed PMID:16831969 .
  187. Paulsen, JS, Hayden, M, Stout, JC, Langbehn, DR, Aylward, E, Ross, CA et al.. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol. 2006;63 (6):883-90. doi: 10.1001/archneur.63.6.883. PubMed PMID:16769871 .
  188. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66 (3):366-72. doi: 10.1212/01.wnl.0000198586.85250.13. PubMed PMID:16476934 .
  189. Paulsen, JS, Hoth, KF, Nehl, C, Stierman, L. Critical periods of suicide risk in Huntington's disease. Am J Psychiatry. 2005;162 (4):725-31. doi: 10.1176/appi.ajp.162.4.725. PubMed PMID:15800145 .
  190. Tumas, V, Camargos, ST, Jalali, PS, Galesso, Ade P, Marques, W Jr. Internal consistency of a Brazilian version of the unified Huntington's disease rating scale. Arq Neuropsiquiatr. 2004;62 (4):977-82. doi: 10.1590/S0004-282X2004000600009. PubMed PMID:15608955 .
  191. Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology. 2004;63 (3):547-9. doi: 10.1212/01.wnl.0000133403.30559.ff. PubMed PMID:15304592 .
  192. Hamilton, JM, Wolfson, T, Peavy, GM, Jacobson, MW, Corey-Bloom, J, Huntington Study Group et al.. Rate and correlates of weight change in Huntington's disease. J Neurol Neurosurg Psychiatry. 2004;75 (2):209-12. doi: 10.1136/jnnp.2003.017822. PubMed PMID:14742590 PubMed Central PMC1738924.
  193. Nehl, C, Paulsen, JS, Huntington Study Group. Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity. J Nerv Ment Dis. 2004;192 (1):72-4. doi: 10.1097/01.nmd.0000106004.67587.57. PubMed PMID:14718780 .
  194. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology. 2003;61 (11):1551-6. doi: 10.1212/01.wnl.0000096019.71649.2b. PubMed PMID:14663041 .
  195. Mahant, N, McCusker, EA, Byth, K, Graham, S, Huntington Study Group. Huntington's disease: clinical correlates of disability and progression. Neurology. 2003;61 (8):1085-92. doi: 10.1212/01.wnl.0000086373.32347.16. PubMed PMID:14581669 .
  196. Wheelock, VL, Tempkin, T, Marder, K, Nance, M, Myers, RH, Zhao, H et al.. Predictors of nursing home placement in Huntington disease. Neurology. 2003;60 (6):998-1001. doi: 10.1212/01.wnl.0000052992.58107.67. PubMed PMID:12654967 .
  197. Djoussé, L, Knowlton, B, Cupples, LA, Marder, K, Shoulson, I, Myers, RH et al.. Weight loss in early stage of Huntington's disease. Neurology. 2002;59 (9):1325-30. doi: 10.1212/01.wnl.0000031791.10922.cf. PubMed PMID:12427878 .
  198. Paulsen, JS, Zhao, H, Stout, JC, Brinkman, RR, Guttman, M, Ross, CA et al.. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology. 2001;57 (4):658-62. doi: 10.1212/wnl.57.4.658. PubMed PMID:11524475 .
  199. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001;57 (3):397-404. doi: 10.1212/wnl.57.3.397. PubMed PMID:11502903 .
  200. Marder, K, Zhao, H, Myers, RH, Cudkowicz, M, Kayson, E, Kieburtz, K et al.. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology. 2000;54 (2):452-8. doi: 10.1212/wnl.54.2.452. PubMed PMID:10668713 .
  201. Anon. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. The Huntington Study Group. Neurology. 1998;50 (5):1366-73. doi: 10.1212/wnl.50.5.1366. PubMed PMID:9595988 .
  202. Anon. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord. 1996;11 (2):136-42. doi: 10.1002/mds.870110204. PubMed PMID:8684382 .
Search PubMed